Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib

Research output: Contribution to journalJournal articleResearchpeer-review

Documents

  • Fulltext

    Final published version, 4.54 MB, PDF document

Metanephric Adenoma (MA) is a rare and unclassifiable renal tumour with sparse reported clinical and morphological features. Generally MA's have a benign course without recurrence after nephrectomy, however a few cases received oncological treatment due to malignant progression. We present a 42-year-old woman who years after an initial nephrectomy developed several processes and biopsy confirmed recurrence of MA. Sunitinib was given for only two weeks, as she developed side-effects and currently the patient undergoes control scans with only minimal growth of the processes. This is the first case of MA treated with Tyrosin-Kinase-Inhibitor.

Original languageEnglish
Article number101880
JournalUrology Case Reports
Volume40
Number of pages4
ISSN2214-4420
DOIs
Publication statusPublished - 2022

    Research areas

  • Metanephric adenoma, Tyrosine kinase inhibitor, Oncology, Renal tumour, ADENOMA

ID: 290109540